Program Description
The treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) is evolving rapidly as the need to slow fibrosis progression and improve long-term outcomes becomes increasingly urgent. While lifestyle and cardiometabolic management remain foundational, newer and emerging pharmacologic options are expanding opportunities to individualize care. Pharmacists need to understand current guidelines to appropriately identify and stage patients, recognize which therapeutic targets are being addressed, and track where therapies are in development to anticipate how practice may change. Key challenges include translating clinical trial end points and eligibility criteria into real-world patient selection and balancing efficacy with adverse event profiles and monitoring requirements. This webinar will equip pharmacists to apply MASH treatment guidelines and deepen knowledge of approved therapies, evaluating late-stage agents and interpreting trial outcomes to translate evidence into real-world patient care. This symposium is the second in the MASLD/MASH curriculum.
Target audience: Specialty and health-system pharmacist
Type of activity: Application
Release date: May 31, 2026
Expiration date: May 31, 2027
Learner level: Foundational
Time to complete activity: 1.0 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Examine the efficacy and safety of currently available therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH)
- Apply current treatment and management guidelines to develop patient-centered care plans for individuals with MASH based on disease stage and comorbidities
- Interpret emerging clinical trial data and therapeutic targets to assess the role of pipeline agents within the evolving MASH treatment landscape
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here